|
| Press Releases |
|
 |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
New-look TGR-WRT launches landmark campaign on legendary rally
Jan 16, 2026 21:34 JST
|
|
|
Mitsubishi Corporation Announces Acquisition of Haynesville Shale Gas Business in Louisiana and Texas
Jan 16, 2026 21:12 JST
|
|
|
Celestion Brings Cutting-Edge Music Technology to Transform Hong Kong's Modern Listening Experience
Jan 16, 2026 19:44 HKT/SGT
|
|
|
Celestion以尖端音響科技革新香港家居聆聽體驗 先進多功能便攜音響系統Hometainer現正熱賣
Jan 16, 2026 19:44 HKT/SGT
|
|
|
日本株、米国株の自動売買取引を、スマホやPCで個人投資家でも簡単に行えるアプリ「Trade Stand（略称：トレスタ）」を大幅アップデート。TradingView自動売買をアプリ内で完結、日本株CFDにも対応。
Jan 16, 2026 17:00: JST
|
|
|
MHI Thermal Systems Expands Lineup of Building-Use Multi-Split Air-Conditioners for Overseas Markets
Jan 16, 2026 15:47 JST
|
|
|
三菱重工サーマルシステムズ、海外市場向けビル用マルチエアコンのラインアップを追加
Jan 16, 2026 13:30: JST
|
|
|
三菱商事、米国テキサス州・ルイジアナ州における ヘインズビルシェールガス事業への参画について
Jan 16, 2026 13:00: JST
|
|
|
三菱造船が開発した自動操船システム“SUPER BRIDGE-X”を搭載 世界初 旅客船における自動運転レベル4相当での商用運航開始
Jan 16, 2026 13:00: JST
|
|
|
興業銀行成功發行全市場首單自貿區主體「玉蘭債」
Jan 16, 2026 10:04 HKT/SGT
|
|
|
First three HKTDC trade fairs of 2026 draw some 82,000 international buyers
Jan 15, 2026 19:46 HKT/SGT
|
|
|
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
|
|
|
真正的賦能者——愛格法醫療於2026年歐洲放射學會議（ECR）展現影像創新風采
Jan 15, 2026 16:00 HKT/SGT
|
|
|
真正的赋能者——爱克发医疗在2026年欧洲放射学大会上展现影像创新力量
Jan 15, 2026 16:00 HKT/SGT
|
|
|
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
